July 29, 2026 Sarepta Therapeutics Expands Leadership with New Inducement Grants for CEO Sarepta Therapeutics has granted substantial equity awards to Dr. Michael Severino, its newly appointed CEO, under its Employment Commencement Incentive Plan. This move aligns with the company's strategy to strengthen leadership and drive growth in genetic medicine, particularly for rare diseases.
July 27, 2026 Sarepta Therapeutics Appoints New CEO: A Strategic Shift in Leadership Sarepta Therapeutics has appointed Dr. Michael Severino as its new CEO, replacing Doug Ingram, who transitions to an advisory role. Severino's extensive experience in biopharmaceuticals positions him to lead the company's mission in advancing genetic medicine for rare diseases.
July 22, 2026 Sarepta Therapeutics Set to Unveil Q2 2026 Financial Results Sarepta Therapeutics is set to announce its Q2 2026 financial results on August 5. A conference call will follow for in-depth discussions on financial performance and strategic initiatives, emphasizing their commitment to rare disease treatments.
June 30, 2026 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sarepta Therapeutics has granted 151,305 RSUs to 30 new employees under its 2024 Employment Commencement Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4). This move aims to attract top talent and signals the company's commitment to innovation in rare disease therapies.
June 30, 2026 Sarepta Therapeutics Announces FDA Acceptance of sNDAs for Duchenne Muscular Dystrophy Treatments Sarepta Therapeutics announced the FDA's acceptance of sNDAs for AMONDYS 45 and VYONDYS 53, therapies designed for Duchenne muscular dystrophy. This acceptance is a step toward converting accelerated approvals into traditional ones, with a PDUFA date of February 2027. Community support highlights the potential impact of these therapies on patient outcomes.
June 01, 2026 Sarepta Therapeutics Set to Engage Investors at Upcoming Conferences Sarepta Therapeutics will engage investors at two key conferences in June 2026, showcasing its advancements in genetic treatments. The company emphasizes its commitment to transparency and innovation in rare disease therapies.
May 06, 2026 Sarepta Therapeutics Inc. Reports Strong Recovery in Q1 2026 Sarepta Therapeutics, Inc. reported a net income of $330.9 million for Q1 2026, a notable recovery from a loss in the previous year. The company achieved significant revenue growth and drastically reduced expenses, while advancing key clinical programs, setting a positive outlook for the future.
May 06, 2026 Sarepta Therapeutics Reports Strong Q1 2026 Results and Advances in Pipeline Sarepta Therapeutics announced strong financial results for Q1 2026, with significant improvements in revenue and operating income. The company is advancing its clinical pipeline, focusing on therapies for rare diseases, and has made strides in regulatory approvals and commercial sales.
April 22, 2026 Sarepta Therapeutics Set to Unveil Q1 2026 Financial Results Sarepta Therapeutics is set to announce its Q1 2026 financial results on May 6, 2026. The event will include a conference call to discuss the company's performance and strategic direction in precision genetic medicine for rare diseases.
March 31, 2026 Sarepta Therapeutics Induces Talent with Strategic Equity Grants Sarepta Therapeutics has granted equity awards to 24 new employees to attract and retain top talent in genetic medicine. This strategic move emphasizes their commitment to combat rare diseases, particularly Duchenne muscular dystrophy, while expanding their workforce. The grants include a structured vesting schedule to align employee incentives with the company's long-term vision.
March 25, 2026 Sarepta Therapeutics Reports Promising Clinical Data for siRNA Programs Targeting Rare Neuromuscular Diseases Sarepta Therapeutics announced encouraging preliminary results from its siRNA programs targeting FSHD and DM1, showing dose-dependent muscle exposure and favorable safety profiles. These groundbreaking therapies may offer hope for patients with rare neuromuscular diseases that currently lack effective treatments.
March 24, 2026 Sarepta Therapeutics Set to Reveal Promising Early Clinical Data Sarepta Therapeutics will present early clinical data on its drug candidates SRP-1001 and SRP-1003 for rare diseases on March 25, 2026. This significant event aims to provide insights into treatments for FSHD1 and DM1, showcasing Sarepta's commitment to advancing genetic medicine.
March 19, 2026 Sarepta Therapeutics Provides Key Regulatory Update on DMD Treatments Sarepta Therapeutics has requested a meeting with the FDA to discuss converting accelerated approvals for its DMD therapies, AMONDYS 45 and VYONDYS 53, to traditional approvals. Supported by clinical data from the ESSENCE study, the company plans to submit supplemental applications by April 2026, aiming to enhance patient access to these essential treatments.
March 16, 2026 Sarepta Therapeutics Launches Cohort 8 of ENDEAVOR Study for Duchenne Muscular Dystrophy Sarepta Therapeutics has launched Cohort 8 of the ENDEAVOR study targeting Duchenne muscular dystrophy. This trial will evaluate a novel immunosuppression regimen with sirolimus for non-ambulant DMD patients, focusing on preventing acute liver injury and assessing the expression of dystrophin protein.
March 02, 2026 Sarepta Therapeutics Inc. Reports Mixed Results in 2025 Annual Report Sarepta Therapeutics' 2025 annual report reveals significant revenue growth amid operational restructuring and regulatory challenges. Despite a net loss of $713.4 million and increased costs, the company is focused on stabilizing its financial position and advancing its innovative therapies.
February 27, 2026 Sarepta Therapeutics Launches 9th Annual Route 79 Scholarship Program Sarepta Therapeutics has launched its 9th Annual Route 79 Scholarship Program, offering scholarships up to $5,000 for individuals with Duchenne muscular dystrophy and their siblings. Applications are open until May 15, 2026, aiming to support their educational aspirations.
February 26, 2026 Sarepta Therapeutics Inc. Set to Showcase Groundbreaking Data at MDA 2026 Sarepta Therapeutics will present key data on gene therapy and exon-skipping treatments for Duchenne muscular dystrophy at the MDA 2026 conference. Highlights include findings from the EMBARK study and caregiver insights, showcasing the company's commitment to advancing genetic medicine.
February 25, 2026 Sarepta Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results Sarepta Therapeutics has reported its financial results for Q4 and full-year 2025, showcasing a strong cash position and advancements in its gene therapy pipeline. Despite a decrease in quarterly revenues, the company remains optimistic about profitability in 2026, driven by successful product launches and clinical trial progress.
February 24, 2026 Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan Sarepta Therapeutics has launched ELEVIDYS, Japan's first gene therapy for Duchenne muscular dystrophy, following its inclusion on the National Health Insurance price list. This collaboration with Chugai Pharmaceutical aims to improve access and treatment outcomes for young patients with specific genetic mutations.
February 24, 2026 Sarepta Therapeutics to Showcase Innovations at TD Cowen Health Care Conference Sarepta Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, showcasing their innovations in genetic medicine for rare diseases. The fireside chat will highlight their commitment to therapies for Duchenne muscular dystrophy and other serious conditions, with a live webcast available for stakeholders.
February 11, 2026 Sarepta Therapeutics Set to Reveal Financial Performance for 2025 Sarepta Therapeutics is set to announce its fourth quarter and full-year financial results for 2025 on February 25, 2026. The company will discuss its performance and future strategies in a conference call, highlighting its commitment to developing therapies for rare diseases.
February 04, 2026 Sarepta Therapeutics Announces Approval for SRP-1005 Clinical Trial in Huntington’s Disease Sarepta Therapeutics has received approval for its SRP-1005 clinical trial aimed at Huntington's Disease, set to begin in Q2 2026. This innovative treatment utilizes advanced delivery mechanisms to target the central nervous system, potentially offering hope to thousands affected by this devastating condition.
January 26, 2026 Sarepta Therapeutics Reports Promising Three-Year Results for ELEVIDYS in Duchenne Muscular Dystrophy Sarepta Therapeutics announced encouraging three-year results from the EMBARK study, demonstrating that ELEVIDYS significantly slows disease progression in young DMD patients. The study highlighted notable improvements in motor functions, reinforcing the therapy's effectiveness and safety.
January 23, 2026 Sarepta Therapeutics to Unveil Groundbreaking Data on ELEVIDYS Gene Therapy Sarepta Therapeutics will present key findings from the EMBARK study on January 26, 2026, showcasing the effectiveness of ELEVIDYS gene therapy for Duchenne muscular dystrophy. This critical data could significantly enhance treatment options for young patients with DMD, emphasizing Sarepta's commitment to innovative therapies.
January 12, 2026 Sarepta Therapeutics Reports Preliminary Financial Results for 2025 Sarepta Therapeutics announced impressive preliminary financial results for 2025, achieving $1.86 billion in total net product revenue. CEO Doug Ingram highlighted the company's resilience and optimism for future growth, particularly with its flagship therapy, ELEVIDYS. The firm remains committed to advancing its innovative pipeline as it heads into 2026.
January 07, 2026 Sarepta Therapeutics Takes a Major Step Forward in Huntington's Disease Treatment Sarepta Therapeutics has submitted a Clinical Trial Application for SRP-1005, targeting Huntington's Disease, with a planned trial starting in 2026. This innovative treatment aims to address the urgent need for effective therapies in a condition currently lacking approved options.
January 05, 2026 Sarepta Therapeutics Set to Present at the 44th Annual J.P. Morgan Healthcare Conference Sarepta Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, discussing advancements in genetic medicine and rare disease treatments. The presentation will include a Q&A session and will be available via live webcast for those unable to attend.
December 11, 2025 Sarepta Therapeutics Announces Strategic Refinancing of Convertible Senior Notes Sarepta Therapeutics has engaged in a strategic refinancing of approximately $291 million in convertible senior notes, converting them into new notes with better terms. This move aims to optimize the company's capital structure and extend its debt maturity, reinforcing its position in the genetic medicine market.
November 25, 2025 Sarepta Therapeutics Announces FDA Approval for ENDEAVOR Cohort 8: A New Era in Duchenne Muscular Dystrophy Treatment Sarepta Therapeutics has gained FDA approval to start Cohort 8 of the ENDEAVOR study, focusing on a new immunosuppressive regimen for Duchenne muscular dystrophy patients. The study aims to reduce liver injury risks while administering the gene therapy ELEVIDYS, marking a significant advancement in DMD treatment protocols.
November 24, 2025 Sarepta Therapeutics Reports Milestones in SRP-1003 Development for Myotonic Dystrophy Sarepta Therapeutics has made significant strides in its Phase 1/2 clinical study of SRP-1003 for Myotonic Dystrophy, completing initial dosing cohorts and advancing to higher doses. The company also achieved a financial milestone by making a $200 million payment to Arrowhead Pharmaceuticals as part of their collaboration.
November 06, 2025 Sarepta Therapeutics Inc. Reports Q3 2025 Financial Results: Navigating Challenges in a Complex Landscape Sarepta Therapeutics reports a significant loss in Q3 2025, driven by decreased revenues and increased expenses amid clinical trials. The company is restructuring and focusing on its robust pipeline to address regulatory challenges and improve financial health.
November 03, 2025 Sarepta Therapeutics Reports Third Quarter 2025 Financial Results and ESSENCE Study Completion Sarepta Therapeutics announced its Q3 2025 financial results and the completion of the ESSENCE study, which evaluated therapies for Duchenne muscular dystrophy. Despite not meeting statistical significance, the study showed promising trends in treatment efficacy. The company reported a net product revenue of $370 million, reflecting a decrease, but remains optimistic about future developments.
October 27, 2025 Sarepta Therapeutics Set to Release Third Quarter 2025 Financial Results Sarepta Therapeutics is set to announce its Q3 2025 financial results on November 3, followed by a conference call to discuss performance and recent developments. The company focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy.
October 03, 2025 Sarepta Therapeutics to Showcase Significant Advances in Neuromuscular Research at WMS 2025 Sarepta Therapeutics will showcase significant advances in neuromuscular research at WMS 2025, revealing data on gene therapies for Duchenne muscular dystrophy and limb-girdle muscular dystrophy. Key presentations will include updates on delandistrogene moxeparvovec and insights into liver injury management strategies.
September 30, 2025 Sarepta Therapeutics Announces Strategic Inducement Grants to New Employees Sarepta Therapeutics has announced equity awards for new employees as part of its strategic growth initiatives, granting 49,805 restricted stock units to attract top talent. This move aligns with their commitment to advancing genetic medicine, particularly for rare diseases like Duchenne muscular dystrophy.
August 06, 2025 Sarepta Therapeutics Reports Strong Growth in Q2 2025 Amidst Regulatory Challenges Sarepta Therapeutics Inc. showcased impressive financial results for Q2 2025, achieving $611 million in revenue, largely driven by its gene therapy, ELEVIDYS. However, regulatory issues and strategic restructuring pose significant challenges for the company moving forward.
May 13, 2025 Sarepta Therapeutics Secures Groundbreaking Approval for ELEVIDYS in Japan Sarepta Therapeutics has achieved a significant milestone with the approval of ELEVIDYS in Japan, marking it as the first gene therapy for Duchenne muscular dystrophy in young children. The therapy shows promising efficacy and safety data, providing a new treatment option for a previously underserved population. This approval represents a pivotal advancement in precision genetic medicine.
May 08, 2025 Sarepta Therapeutics Inc. to Showcase Innovations at BofA Securities Health Care Conference Sarepta Therapeutics will participate in the BofA Securities Health Care Conference on May 14, 2025. The event will showcase their advancements in genetic therapies for rare diseases, emphasizing their commitment to investor engagement and innovation.
May 06, 2025 Sarepta Therapeutics Reports Q1 2025 Financial Results: A Mixed Bag of Growth and Challenges Sarepta Therapeutics reported a substantial revenue increase to $744.8 million in Q1 2025, primarily driven by the success of its product ELEVIDYS. However, rising R&D expenses led to a net loss of $447.5 million, presenting challenges for the company's financial health moving forward.
May 06, 2025 Sarepta Therapeutics Reports Strong Q1 2025 Financial Results Amid Strategic Developments Sarepta Therapeutics reported a significant 70% revenue increase in Q1 2025, driven by strong sales of its therapies. Despite operational losses, the company is optimistic about its future with strategic collaborations and a robust pipeline for rare diseases.
April 22, 2025 Sarepta Therapeutics Set to Reveal Q1 2025 Financial Results Sarepta Therapeutics is set to announce its Q1 2025 financial results on May 6, 2025. The company will also host a conference call to discuss these results, emphasizing its commitment to transparency and innovation in treating rare diseases.
April 21, 2025 Sarepta Therapeutics Under Investigation Amidst Controversy Surrounding ELEVIDYS Sarepta Therapeutics is under investigation following the death of a young DMD patient after receiving ELEVIDYS. This has led to a significant stock drop and scrutiny over the company’s disclosures. The Schall Law Firm is investigating potential securities law violations, raising concerns about the company’s future.
April 15, 2025 Sarepta Therapeutics Advances Gene Therapy Programs for Limb-Girdle Muscular Dystrophy Sarepta Therapeutics has made major progress in gene therapies for limb-girdle muscular dystrophy (LGMD), receiving FDA clearance for new trials. With no approved therapies available, Sarepta's initiatives aim to meet critical medical needs and transform treatment options for LGMD patients.
April 09, 2025 Sarepta Therapeutics Faces Investor Scrutiny Following Tragic Incident Sarepta Therapeutics is facing intense scrutiny after a 16-year-old patient died from acute liver failure following treatment with its gene therapy, ELEVIDYS. This incident has led to a significant drop in stock prices and prompted a legal investigation into potential violations of federal securities laws. The company must address these concerns to restore investor confidence.
April 04, 2025 Sarepta Therapeutics Provides Update on ELEVIDYS Amid Regulatory Scrutiny Sarepta Therapeutics has issued a safety update on ELEVIDYS, its gene therapy for Duchenne muscular dystrophy, amid regulatory scrutiny. While clinical studies are temporarily halted, an independent committee has recommended continuing dosing, indicating a positive outlook for the therapy despite safety concerns.
March 31, 2025 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sarepta Therapeutics has granted equity awards to 39 new employees as part of its strategy to attract top talent in precision genetic medicine. The awards include stock options and RSUs with a structured vesting schedule, reinforcing the company's commitment to innovation in treating rare diseases.
February 28, 2025 Sarepta Therapeutics Launches 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics has opened applications for its 8th Annual Route 79 Duchenne Scholarship Program, offering up to $5,000 to 20 individuals diagnosed with Duchenne muscular dystrophy and support for their siblings. This initiative highlights the importance of education for the Duchenne community.
February 28, 2025 Sarepta Therapeutics Inc. 2024 Annual Report: A Year of Growth and Strategic Expansion Sarepta Therapeutics reported a significant revenue increase in 2024, reaching $1.15 billion, thanks to the successful launch of ELEVIDYS. The company also improved its profitability, turning a net income of $235.2 million, while investing heavily in R&D despite facing legal challenges.
February 14, 2025 Sarepta Therapeutics Secures $600 Million Credit Facility to Fuel Growth Sarepta Therapeutics has secured a $600 million credit facility to strengthen its financial position and support its Sarepta 2030 initiative. This funding will aid in advancing its pipeline for rare diseases, reflecting strong lender confidence in the company's future prospects.
February 12, 2025 Sarepta Therapeutics Set to Announce Fourth Quarter and Full-Year 2024 Financial Results Sarepta Therapeutics is set to release its fourth quarter and full-year 2024 financial results on February 26, 2025. Following the announcement, a conference call will provide insights into the company's performance and strategic direction, emphasizing its commitment to transparency and investor engagement.
February 04, 2025 SWOT Analysis of Sarepta Therapeutics Inc in 2025 This SWOT analysis of Sarepta Therapeutics Inc in 2025 highlights the company's strengths in innovative therapies and market leadership in DMD, while addressing financial vulnerabilities and competitive threats. It outlines potential growth opportunities in expanding therapeutic areas and global markets.
November 06, 2024 Sarepta Therapeutics Inc. Reports Strong Q3 2024 Results Amid Increased Demand for Gene Therapy Products Sarepta Therapeutics Inc. reported net revenues of $467.1 million for Q3 2024, a 41% increase from the previous year, fueled by the success of its gene therapy product, ELEVIDYS. The company's strategic focus on R&D and operational efficiency has strengthened its financial foundation, positioning it well for future growth in the biopharmaceutical sector.
August 07, 2024 Sarepta Therapeutics Inc. Reports Strong Q2 2024 Results Sarepta Therapeutics reported impressive Q2 2024 results, with net revenues of $121.6 million driven by the successful launch of ELEVIDYS. The company demonstrates effective cost management and a strong cash position, positioning itself for future growth in innovative therapies for rare diseases.
May 01, 2024 Sarepta Therapeutics Inc. Q1 2024 Financial Report: A Strong Start Fueled by Product Innovations Sarepta Therapeutics Inc. reported impressive Q1 2024 results with $1.24 billion in net product revenues, driven by the launch of ELEVIDYS. The company also experienced a significant recovery in net income, highlighting improved operational efficiency and a strong cash position for future growth.
